Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01355497 · ClinicalTrials.gov registry record · Phase 3
Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum
A Phase 3 study, sponsored by GTx.
- Completed
- Registry status
- Phase 3
- Development phase
- 330
- Enrollment target
NCT01355497: Completed Phase 3 study, sponsored by GTx.
NCT01355497 is a Phase 3 study that has completed, run by GTx. The registered enrollment target is 330 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (57% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01355497, a Phase 3 study, has completed, sponsored by GTx.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 330 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if the investigational drug GTx-024 can help patients with non small cell lung cancer increase physical function and maintain or gain muscle.
Primary Outcome
Measure is the percentage of subjects at day 84 with stair climb power change \>=10% from their baseline value.
Interventions
- DRUG placebo
- DRUG GTx-024
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 330 participants |
| Start Date | 2011-07 |
| Est. Completion | 2014-06 |
| Phase | Phase 3 |
What the finished NCT01355497 record still lists
NCT01355497 is an interventional study that assigns participants to a tested intervention. The registered 330 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (57% lower).
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT01355497 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01355497 about?
NCT01355497 is a clinical study titled "Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum". The purpose of this study is to determine if the investigational drug GTx-024 can help patients with non small cell lung cancer increase physical function and maintain or gain muscle.
What is the current status of trial NCT01355497?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 330 participants. The study started on 2011-07. Estimated completion is 2014-06.
What interventions are being tested in trial NCT01355497?
The interventions under investigation include: placebo (DRUG), GTx-024 (DRUG).
Who is sponsoring clinical trial NCT01355497?
This trial is sponsored by GTx, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01355497's enrollment target sits among peer trials
330 1066th of 2000 higher than 927 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00359684 · 330 participants
Use of Cysteamine in the Treatment of Cystinosis
- NCT03817502 · 330 participants · Phase 3
Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia
- NCT03922724 · 330 participants · Phase 2
Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma
- NCT03932773 · 330 participants · NA
Multi-site Confirmatory Efficacy Treatment Trial of Combat-related PTSD
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia